Journal Article

Retrospective non-inferiority study of stereotactic radiosurgery for more than ten brain metastases

Nagai, Naoya, Hashimoto, Shingo, Tachibana, Hiroyuki, Shindo, Yurika, Koide, Yutaro, Ishihara, Shunichi, Naganawa, Shinji, Kodaira, Takeshi

2023

Overview

Aim This study aimed to investigate the clinical benefits of stereotactic radiosurgery (SRS) in patients with > 10 brain metastases (BM) compared to patients with 2–10 BM. Methods The study included multiple BM patients who underwent SRS between 2014 and 2022, excluding patients who underwent whole brain radiotherapy, had a Karnofsky Performance Status score < 60, suspected leptomeningeal disease, or a single BM lesion. Patients were divided into two groups (2–10 and > 10 BM groups) and matched 2:1 based on propensity scores. The primary endpoint was overall survival (OS) in the matched dataset, with intracranial progression-free survival (PFS) as the secondary endpoint. Non-inferiority was established if the upper limit of the 95% confidence interval (CI) of the adjusted hazard ratio was below 1.3. Results Of the 1042 patients identified, 434 met eligibility criteria. After propensity score matching, 240 patients were analyzed (160 in the BM 2–10 group and 80 in the > 10 BM group). The median OS was 18.2 months in the 2–10 BM group and 19.4 months in the > 10 BM group (P = 0.60). The adjusted hazard ratio was 0.86 (95% CI: 0.59–1.24), indicating non-inferiority. PFS was not significantly different between the groups (4.8 months vs. 4.8 months, P = 0.94). The number of BM did not significantly impact OS or PFS. Conclusions SRS for selected patients with > 10 BM was non-inferior in terms of OS compared to those with 2–10 BM in a propensity score-matched dataset.

• Publisher: Springer US,Springer Nature B.V
• Subject: Brain cancer / Medicine / Medicine & Public Health / Meninges / Metastases / Metastasis / Neurology / Oncology / Radiation therapy / Radiosurgery / Survival